Country

Clinical trials in Japan

Active obesity and GLP-1 studies with at least one location in Japan.

30active studies

12recruiting now

32countries represented

117largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

OsteoarthritisCondition

Orforglipron, PlaceboTreatment

Canada, China88 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07153471See eligibility →

Recruiting nowPhase 3

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

Obesity, Overweight and/or ObesityCondition

PF-08653944, PlaceboTreatment

Brazil, Canada50 locations

PfizerSponsor

Updated 2026-09-04 · NCT07595549See eligibility →

Recruiting nowPhase 3

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Obesity, OverweightCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Japan87 locations

AmgenSponsor

Updated 2026-09-03 · NCT07684235See eligibility →

Recruiting nowPhase 3

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

Obesity, OverweightCondition

Maridebart Cafraglutide, PlaceboTreatment

Japan, Puerto Rico37 locations

AmgenSponsor

Updated 2026-09-03 · NCT07684144See eligibility →

Recruiting nowPhase 3

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Belgium, Brazil117 locations

Eli Lilly and CompanySponsor

Updated 2026-08-24 · NCT06672549See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Israel, Italy34 locations

Eli Lilly and CompanySponsor

Updated 2026-08-24 · NCT06672939See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

Obstructive Sleep ApneaCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Brazil57 locations

AmgenSponsor

Updated 2026-08-14 · NCT07226765See eligibility →

Recruiting nowPhase 2

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

NNC0662-0419, SemaglutideTreatment

Croatia, Hungary63 locations

Novo Nordisk A/SSponsor

Updated 2026-08-10 · NCT07415954See eligibility →

Recruiting nowPhase 3

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, China92 locations

Novo Nordisk A/SSponsor

Updated 2026-08-04 · NCT07571109See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

Obesity, Obstructive Sleep ApneaCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Brazil61 locations

AmgenSponsor

Updated 2026-08-04 · NCT07225686See eligibility →

Recruiting nowPhase 1

A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Japanese Healthy People and Japanese People With Obesity or Overweight

Healthy, ObesityCondition

BI 3034701, PlaceboTreatment

Japan3 locations

Boehringer IngelheimSponsor

Updated 2026-07-24 · NCT07693231See eligibility →

Recruiting nowNot applicable

Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2

Type 2 Diabetes Mellitus (T2DM), Type 2 DiabetesCondition

Intervention not listedTreatment

Japan1 locations

Osaka Metropolitan UniversitySponsor

Updated 2024-12-04 · NCT06694012See eligibility →

Opening soonPhase 3

A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)

ObesityCondition

Berobenatide, PlaceboTreatment

Japan12 locations

PfizerSponsor

Updated 2026-09-04 · NCT07794761See eligibility →

Opening soonPhase 3

A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)

ObesityCondition

Berobenatide, PlaceboTreatment

Japan11 locations

PfizerSponsor

Updated 2026-09-04 · NCT07794774See eligibility →

Opening soonPhase 2

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

Atherosclerosis, Cardiovascular DiseaseCondition

Clazakizumab, PlaceboTreatment

Argentina, Japan47 locations

Eli Lilly and CompanySponsor

Updated 2026-08-25 · NCT07783802See eligibility →

Opening soonPhase 3

AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight

Obesity, OverweightCondition

Zenagamtide, Placebo ( matched to Zenagamtide)Treatment

India, Japan44 locations

Novo Nordisk A/SSponsor

Updated 2026-08-24 · NCT07668401See eligibility →

Opening soonPhase 3

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

Obesity or Overweight, Weight-Related ComorbidityCondition

AZD6234, PlaceboTreatment

Argentina, Brazil88 locations

AstraZenecaSponsor

Updated 2026-08-20 · NCT07776509See eligibility →

Opening soonPhase 3

A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

Orforglipron, DulaglutideTreatment

Belgium, Brazil71 locations

Eli Lilly and CompanySponsor

Updated 2026-08-19 · NCT07668336See eligibility →

Opening soonPhase 1

A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes

Obesity, OverweightCondition

Macupatide, EloralintideTreatment

Japan3 locations

Eli Lilly and CompanySponsor

Updated 2026-08-14 · NCT07765511See eligibility →

Opening soonNot applicable

Cities for Better Health Childhood Obesity Prevention Initiative in JAPAN

Quality of Life (QOL), NutritionCondition

Multi-level, Multi-component Intervention PackageTreatment

Japan1 locations

Chiba UniversitySponsor

Updated 2025-07-11 · NCT07061665See eligibility →

Invitation onlyNot applicable

Cities for Better Health Childhood Obesity Prevention Initiative

ObesityCondition

Community-based intervention packagesTreatment

Australia, Brazil6 locations

Novo Nordisk A/SSponsor

Updated 2026-08-21 · NCT06855563See eligibility →

Active, not recruitingPhase 1, Phase 2

A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight

Overweight and ObesityCondition

AZD9550, placeboTreatment

Austria, Canada15 locations

AstraZenecaSponsor

Updated 2026-08-26 · NCT06151964See eligibility →

Active, not recruitingPhase 3

A Trial of Setmelanotide in Acquired Hypothalamic Obesity

Hypothalamic ObesityCondition

Setmelanotide, PlaceboTreatment

Canada, Germany28 locations

Rhythm Pharmaceuticals, Inc.Sponsor

Updated 2026-08-10 · NCT05774756See eligibility →

Active, not recruitingPhase 3

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-07-31 · NCT06993792See eligibility →

Active, not recruitingPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-07-29 · NCT06972459See eligibility →

Active, not recruitingPhase 1

A Study of LY3971297 in Healthy Participants

Healthy, ObesityCondition

LY3971297, PlaceboTreatment

Japan, Singapore7 locations

Eli Lilly and CompanySponsor

Updated 2026-07-16 · NCT06148272See eligibility →

Active, not recruitingNot applicable

Special Use - Results Surveillance on Long-term Use With Wegovy®

ObesityCondition

SemaglutideTreatment

Japan112 locations

Novo Nordisk A/SSponsor

Updated 2026-04-22 · NCT06283667See eligibility →

Active, not recruitingPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-04-20 · NCT06972472See eligibility →

Active, not recruitingPhase 3

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease

Obesity DiseaseCondition

Maridebart cafraglutide, PlaceboTreatment

Japan30 locations

AmgenSponsor

Updated 2025-12-17 · NCT06987695See eligibility →

Active, not recruitingPhase 3

A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

OSA, Overweight or ObesityCondition

Orforglipron, PlaceboTreatment

Argentina, Brazil66 locations

Eli Lilly and CompanySponsor

Updated 2025-09-29 · NCT06649045See eligibility →

Related countries

United States1,107 China326 Canada158 France110 Spain98 Germany95

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.